Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy

Since 2005, major progresses have been made in the neoadjuvant treatment of HER2-positive breast cancer. Trastuzumab introduction associated with chemotherapy has been the first major step leading to the improvement of the complete pathological response rate and, like in the adjuvant studies, better...

Descripción completa

Detalles Bibliográficos
Autores principales: Guiu, S., Mouret Reynier, M. A., Toure, M., Coudert, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657410/
https://www.ncbi.nlm.nih.gov/pubmed/23737784
http://dx.doi.org/10.1155/2013/854121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3657410/
https://www.ncbi.nlm.nih.gov/pubmed/23737784
http://dx.doi.org/10.1155/2013/854121

Ejemplares similares